/PRNewswire/ Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and.
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Industry veteran with expertise in oncology and immuno-oncology and a strong track record of advancing programs through clinical development
PHILADELPHIA, May 2, 2024 /PRNewswire/ Carisma.
Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 One-year ROMAN follow-up data presented at 2022 American Society for Radiation.